JP2022540759A5 - - Google Patents
Info
- Publication number
- JP2022540759A5 JP2022540759A5 JP2021576081A JP2021576081A JP2022540759A5 JP 2022540759 A5 JP2022540759 A5 JP 2022540759A5 JP 2021576081 A JP2021576081 A JP 2021576081A JP 2021576081 A JP2021576081 A JP 2021576081A JP 2022540759 A5 JP2022540759 A5 JP 2022540759A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- patients
- treatment
- metastatic melanoma
- melanoma cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19182813.6 | 2019-06-27 | ||
| EP19182813 | 2019-06-27 | ||
| PCT/EP2020/068217 WO2020260685A1 (en) | 2019-06-27 | 2020-06-29 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540759A JP2022540759A (ja) | 2022-09-20 |
| JP2022540759A5 true JP2022540759A5 (https=) | 2023-06-07 |
Family
ID=67253658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576081A Pending JP2022540759A (ja) | 2019-06-27 | 2020-06-29 | 併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220387573A1 (https=) |
| EP (1) | EP3990008A1 (https=) |
| JP (1) | JP2022540759A (https=) |
| KR (1) | KR20220061946A (https=) |
| CN (1) | CN114340659B (https=) |
| AU (1) | AU2020301582A1 (https=) |
| BR (1) | BR112021025170A2 (https=) |
| CA (1) | CA3144296A1 (https=) |
| IL (1) | IL289130A (https=) |
| MX (1) | MX2021015802A (https=) |
| WO (1) | WO2020260685A1 (https=) |
| ZA (1) | ZA202200731B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210386843A1 (en) * | 2019-01-04 | 2021-12-16 | Etherna Immunotherapies Nv | mRNA Vaccine |
| WO2020182993A1 (en) * | 2019-03-13 | 2020-09-17 | Etherna Immunotherapies Nv | Mrna vaccine |
| WO2025260013A1 (en) * | 2024-06-13 | 2025-12-18 | Yale University | Compositions and methods of mrna-based adjuvants for mrna vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| EP2201100B1 (en) * | 2007-09-14 | 2016-03-16 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| HUE058792T2 (hu) | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| AU2017257254B2 (en) * | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
-
2020
- 2020-06-29 CA CA3144296A patent/CA3144296A1/en active Pending
- 2020-06-29 BR BR112021025170A patent/BR112021025170A2/pt unknown
- 2020-06-29 MX MX2021015802A patent/MX2021015802A/es unknown
- 2020-06-29 WO PCT/EP2020/068217 patent/WO2020260685A1/en not_active Ceased
- 2020-06-29 US US17/620,271 patent/US20220387573A1/en not_active Abandoned
- 2020-06-29 EP EP20737377.0A patent/EP3990008A1/en not_active Withdrawn
- 2020-06-29 KR KR1020227002930A patent/KR20220061946A/ko active Pending
- 2020-06-29 AU AU2020301582A patent/AU2020301582A1/en not_active Abandoned
- 2020-06-29 JP JP2021576081A patent/JP2022540759A/ja active Pending
- 2020-06-29 CN CN202080044905.2A patent/CN114340659B/zh active Active
-
2021
- 2021-12-19 IL IL289130A patent/IL289130A/en unknown
-
2022
- 2022-01-14 ZA ZA2022/00731A patent/ZA202200731B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niezgoda et al. | Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy | |
| Chen et al. | Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions | |
| TWI910495B (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| Akerley et al. | Phase I trial of weekly paclitaxel in advanced lung cancer. | |
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2022540759A5 (https=) | ||
| Exposito et al. | CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation | |
| CN114746117A (zh) | 抗dll3药剂的给药方案 | |
| JP2023036999A (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| Mok et al. | P1. 04-008 POSEIDON: a phase 3 study of first-line durvalumab±tremelimumab+ chemotherapy vs chemotherapy alone in metastatic NSCLC | |
| JP7240512B2 (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| Lüttmann et al. | Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition | |
| Yung et al. | A pilot study of recombinant interferon beta (IFN-βser) in patients with recurrent glioma | |
| Kothari et al. | Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects | |
| WO2024183817A1 (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| JP2017530132A5 (https=) | ||
| Sabbatini | Consolidation therapy in ovarian cancer: a clinical update | |
| US20250268863A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| Patt et al. | A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| EP4319815A1 (en) | Dosing of bispecific t cell engager | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 |